

Jesus Guinea

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6176931/jesus-guinea-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

180
papers

6,395
citations

41
h-index

74
g-index

208
ext. papers

8,033
ext. citations

5.9
avg, IF

5.91
L-index

#	Paper	IF	Citations
180	Comment on: Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes.. <i>Journal of Antimicrobial Chemotherapy</i> , 2022 ,	5.1	0
179	The current state of clinical mycology in Africa: a European Confederation of Medical Mycology and International Society for Human and Animal Mycology survey. <i>Lancet Microbe</i> , 2022 ,	22.2	3
178	Prognostic factors of Candida spp. bloodstream infection in adults: A nine-year retrospective cohort study across tertiary hospitals in Brazil and Spain. <i>The Lancet Regional Health Americas</i> , 2022 , 6, 100117		1
177	Incidence of Candidemia Is Higher in COVID-19 versus Non-COVID-19 Patients, but Not Driven by Intrahospital Transmission.. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8,	5.6	4
176	Fluconazole-resistant Candida parapsilosis clonally related genotypes: first report proving the presence of endemic isolates harbouring the Y132F ERG11 gene substitution in Spain.. <i>Clinical Microbiology and Infection</i> , 2022 ,	9.5	1
175	Impact of the COVID-19 Pandemic on the Clinical Profile of Candidemia and the Incidence of Fungemia Due to Fluconazole-Resistant Candida parapsilosis. <i>Journal of Fungi (Basel, Switzerland)</i> , 2022 , 8, 451	5.6	2
174	Case Report: Severe ARDS in a Pediatric Hematopoietic Stem-Cell Transplantation Recipient Caused by Disseminated Toxoplasmosis.. <i>Frontiers in Pediatrics</i> , 2021 , 9, 810718	3.4	0
173	Spectrophotometric azole and amphotericin B MIC readings against Aspergillus fumigatus sensu lato using the EUCAST 9.3.2 methodology. Are 90 and 95% fungal growth inhibition endpoints equally suitable?. <i>Medical Mycology</i> , 2021 , 60,	3.9	1
172	In vitro activity of ibrexafungin against Candida species isolated from blood cultures. Determination of wild-type populations using the EUCAST method. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	1
171	Monitoring the Epidemiology and Antifungal Resistance of Yeasts Causing Fungemia in a Tertiary Care Hospital in Madrid, Spain: Any Relevant Changes in the Last 13 Years?. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65,	5.9	5
170	Multicenter evaluation of the Panbio COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	43
169	Detection of azole resistance in Aspergillus fumigatus complex isolates using MALDI-TOF mass spectrometry. <i>Clinical Microbiology and Infection</i> , 2021 ,	9.5	2
168	In vitro activity of ibrexafungin and comparators against Candida albicans genotypes from vaginal samples and blood cultures. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 915.e5-915.e8	9.5	4
167	Azole-Resistant Aspergillus fumigatus Clinical Isolate Screening in Azole-Containing Agar Plates (EUCAST E.Def 10.1): Low Impact of Plastic Trays Used and Poor Performance in Cryptic Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0048221	5.9	0
166	How to: perform antifungal susceptibility testing of microconidia-forming dermatophytes following the new reference EUCAST method E.Def 11.0, exemplified by Trichophyton. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 55-60	9.5	16
165	Invasive pulmonary aspergillosis in the COVID-19 era: An expected new entity. <i>Mycoses</i> , 2021 , 64, 132-143	5.2	73
164	Utility of 1,3 β -D-Glucan Assay for Guidance in Antifungal Stewardship Programs for Oncologic Patients and Solid Organ Transplant Recipients. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	4

163	Etest ECVs/ECOFFs for Detection of Resistance in Prevalent and Three Nonprevalent spp. to Triazoles and Amphotericin B and Aspergillus spp. to Caspofungin: Further Assessment of Modal Variability. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0109321	5.9	1
162	Azole resistance survey on clinical Aspergillus fumigatus isolates in Spain. <i>Clinical Microbiology and Infection</i> , 2021 , 27, 1170.e1-1170.e7	9.5	13
161	Antifungal Susceptibility Testing Identifies the Abdominal Cavity as a Source of Candida glabrata-Resistant Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2021 , 65, e0124921	5.9	4
160	Lack of relationship between genotype and virulence in Candida species. <i>Revista Iberoamericana De Micologia</i> , 2021 , 38, 9-11	1.6	
159	First Report of an Invasive Infection by in a Neutropenic Patient with Hematological Malignancy under Chemotherapy.. <i>Journal of Fungi (Basel, Switzerland)</i> , 2021 , 7,	5.6	
158	Updated EUCAST Clinical Breakpoints against , Implications for the Clinical Microbiology Laboratory. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	6
157	Genotyping Reveals High Clonal Diversity and Widespread Genotypes of Causing Candidemia at Distant Geographical Areas. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020 , 10, 166	5.9	7
156	How to interpret MICs of antifungal compounds according to the revised clinical breakpoints v. 10.0 European committee on antimicrobial susceptibility testing (EUCAST). <i>Clinical Microbiology and Infection</i> , 2020 , 26, 1464-1472	9.5	56
155	Revision of EUCAST breakpoints: consequences for susceptibility of contemporary Danish mould isolates to isavuconazole and comparators. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 2573-2581	5.1	1
154	Outbreak of COVID-19 in a nursing home in Madrid. <i>Journal of Infection</i> , 2020 , 81, 647-679	18.9	25
153	Candidemia Candida albicans clusters have higher tendency to form biofilms than singleton genotypes \square <i>Medical Mycology</i> , 2020 , 58, 887-895	3.9	1
152	Therapeutic Drug Monitoring of Antifungal Drugs: Another Tool to Improve Patient Outcome?. <i>Infectious Diseases and Therapy</i> , 2020 , 9, 137-149	6.2	16
151	Recommendations of the Spanish Antibiogram Committee (COESANT) for selecting antimicrobial agents and concentrations for in vitro susceptibility studies using automated systems. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 , 38, 182-187	0.9	0
150	Two serological approaches for detection of antibodies to SARS-CoV-2 in different scenarios: a screening tool and a point-of-care test. <i>Diagnostic Microbiology and Infectious Disease</i> , 2020 , 98, 115167	2.9	14
149	From CLSI to EUCAST, a necessary step in Spanish laboratories. <i>Enfermedades Infecciosas Y Microbiología Clínica (English Ed)</i> , 2020 , 38, 79-83	0.1	
148	Susceptibility of uncommon Candida species to systemic antifungals by the EUCAST methodology. <i>Medical Mycology</i> , 2020 , 58, 848-851	3.9	2
147	Azole and Amphotericin B MIC Values against : High Agreement between Spectrophotometric and Visual Readings Using the EUCAST EDef 9.3.2 Procedure. <i>Antimicrobial Agents and Chemotherapy</i> , 2020 , 65,	5.9	4
146	Detection of SARS-CoV-2 antibodies is insufficient for the diagnosis of active or cured COVID-19. <i>Scientific Reports</i> , 2020 , 10, 19893	4.9	17

145	Invasive <i>Scedosporium</i> and <i>Lomentosora</i> infections in the era of antifungal prophylaxis: A 20-year experience from a single centre in Spain. <i>Mycoses</i> , 2020 , 63, 1195	5.2	3
144	Implementation of MALDI-TOF Mass Spectrometry and Peak Analysis: Application to the Discrimination of Species Complex and Their Interspecies Hybrids. <i>Journal of Fungi (Basel, Switzerland)</i> , 2020 , 6,	5.6	4
143	From CLSI to EUCAST, a necessary step in Spanish laboratories. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2020 , 38, 79-83	0.9	3
142	A retrospective cohort of invasive fusariosis in the era of antimould prophylaxis. <i>Medical Mycology</i> , 2020 , 58, 300-309	3.9	6
141	<i>Candida</i> isolates causing candidemia show different degrees of virulence in <i>Galleria mellonella</i> . <i>Medical Mycology</i> , 2020 , 58, 83-92	3.9	10
140	Clinical Relevance and Prognostic Value of Persistently Negative (1,3)- β -D-Glucan in Adults With Candidemia: A 5-year Experience in a Tertiary Hospital. <i>Clinical Infectious Diseases</i> , 2020 , 70, 1925-1932	11.6	9
139	Multicentre validation of a EUCAST method for the antifungal susceptibility testing of microconidia-forming dermatophytes. <i>Journal of Antimicrobial Chemotherapy</i> , 2020 , 75, 1807-1819	5.1	16
138	Successful Treatment of Severe Aspergillosis with Isavuconazole Therapy after Allogeneic Stem Cell Transplantation. <i>Chemotherapy</i> , 2019 , 64, 57-61	3.2	2
137	Persistent Candidemia in adults: underlying causes and clinical significance in the antifungal stewardship era. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2019 , 38, 607-614	5.3	13
136	Fatal disseminated infection by <i>Gymnascella hyalinospora</i> in a heart transplant recipient. <i>Transplant Infectious Disease</i> , 2019 , 21, e13128	2.7	1
135	Executive summary of clinical practice guideline for the management of invasive diseases caused by <i>Aspergillus</i> : 2018 Update by the GEMICOMED-SEIMC/REIPI. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2019 , 37, 535-541	0.9	18
134	Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome. <i>Transplant Infectious Disease</i> , 2019 , 21, e13195	2.7	7
133	Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. <i>Lancet Infectious Diseases</i> , 2019 , 19, e405-e421	25.5	441
132	Fluconazole resistance is not a predictor of poor outcome in patients with cryptococcosis. <i>Mycoses</i> , 2019 , 62, 441-449	5.2	9
131	Assessment of the anti-biofilm effect of micafungin in an animal model of catheter-related candidemia. <i>Medical Mycology</i> , 2019 , 57, 496-503	3.9	1
130	Does the composition of polystyrene trays affect <i>Candida</i> spp. biofilm formation?. <i>Medical Mycology</i> , 2019 , 57, 504-509	3.9	2
129	Detection of Echinocandin-Resistant in Blood Cultures Spiked with Different Percentages of Mutants. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	4
128	Gene Point Mutations Are Not Antifungal Resistance Markers in. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	15

127	How to: EUCAST recommendations on the screening procedure E.Def 10.1 for the detection of azole resistance in <i>Aspergillus fumigatus</i> isolates using four-well azole-containing agar plates. <i>Clinical Microbiology and Infection</i> , 2019 , 25, 681-687	9.5	42
126	Method-Dependent Epidemiological Cutoff Values for Detection of Triazole Resistance in and Species for the Sensititre YeastOne Colorimetric Broth and Etest Agar Diffusion Methods. <i>Antimicrobial Agents and Chemotherapy</i> , 2019 , 63,	5.9	37
125	Increased species-assignment of filamentous fungi using MALDI-TOF MS coupled with a simplified sample processing and an in-house library. <i>Medical Mycology</i> , 2019 , 57, 63-70	3.9	23
124	Is biofilm production a prognostic marker in adults with candidaemia?. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1010-1015	9.5	14
123	Fungaemia caused by rare yeasts: incidence, clinical characteristics and outcome over 10 years. <i>Journal of Antimicrobial Chemotherapy</i> , 2018 , 73, 823-825	5.1	2
122	Posaconazole MIC Distributions for <i>Aspergillus fumigatus</i> Species Complex by Four Methods: Impact of Mutations on Estimation of Epidemiological Cutoff Values. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	18
121	Mutant Prevention Concentration and Mutant Selection Window of Micafungin and Anidulafungin in Clinical <i>Candida glabrata</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	13
120	Low and constant micafungin concentrations may be sufficient to lead to resistance mutations in FKS2 gene of <i>Candida glabrata</i> . <i>Medical Mycology</i> , 2018 , 56, 903-906	3.9	11
119	Resistance to Echinocandins in <i>Candida</i> Can Be Detected by Performing the Etest Directly on Blood Culture Samples. <i>Antimicrobial Agents and Chemotherapy</i> , 2018 , 62,	5.9	6
118	Multicentre determination of rezafungin (CD101) susceptibility of <i>Candida</i> species by the EUCAST method. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1200-1204	9.5	18
117	Microbiological diagnosis of biofilm-related infections. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2018 , 36, 375-381	0.9	14
116	Reduction in Percentage of Clusters of <i>Candida albicans</i> and <i>Candida parapsilosis</i> Causing Candidemia in a General Hospital in Madrid, Spain. <i>Journal of Clinical Microbiology</i> , 2018 , 56,	9.7	11
115	Donor-derived invasive aspergillosis after kidney transplant. <i>Medical Mycology Case Reports</i> , 2018 , 22, 24-26	1.7	1
114	Comparison of Two Highly Discriminatory Typing Methods to Analyze Azole Resistance. <i>Frontiers in Microbiology</i> , 2018 , 9, 1626	5.7	17
113	Growth kinetics in <i>Candida</i> spp.: Differences between species and potential impact on antifungal susceptibility testing as described by the EUCAST. <i>Medical Mycology</i> , 2018 ,	3.9	1
112	Isavuconazole is highly active <i>in vitro</i> against <i>Candida</i> species isolates but shows trailing effect. <i>Clinical Microbiology and Infection</i> , 2018 , 24, 1343.e1-1343.e4	9.5	9
111	Inonotosis in Patient with Hematologic Malignancy. <i>Emerging Infectious Diseases</i> , 2018 , 24, 180-182	10.2	3
110	Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 672.e1-672.e11	9.5	17

109	The Etest Performed Directly on Blood Culture Bottles Is a Reliable Tool for Detection of Fluconazole-Resistant <i>Candida albicans</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	10
108	The misleading effect of serum galactomannan testing in high-risk haematology patients receiving prophylaxis with micafungin. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 1000.e1-1000.e4	9.5	23
107	<i>Candida guilliermondii</i> Complex Is Characterized by High Antifungal Resistance but Low Mortality in 22 Cases of Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	16
106	Emerging multidrug-resistant <i>Candida</i> species. <i>Current Opinion in Infectious Diseases</i> , 2017 , 30, 528-538	5.4	83
105	Increasing incidence of mucormycosis in a large Spanish hospital from 2007 to 2015: Epidemiology and microbiological characterization of the isolates. <i>PLoS ONE</i> , 2017 , 12, e0179136	3.7	69
104	The novel oral glucan synthase inhibitor SCY-078 shows in vitro activity against sessile and planktonic <i>Candida</i> spp. <i>Journal of Antimicrobial Chemotherapy</i> , 2017 , 72, 1969-1976	5.1	22
103	Multicenter Study of Method-Dependent Epidemiological Cutoff Values for Detection of Resistance in <i>Candida</i> spp. and <i>Aspergillus</i> spp. to Amphotericin B and Echinocandins for the Etest Agar Diffusion Method. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	30
102	Frequency of the Paradoxical Effect Measured Using the EUCAST Procedure with Micafungin, Anidulafungin, and Caspofungin against <i>Candida</i> Species Isolates Causing Candidemia. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	8
101	Genotyping of <i>Aspergillus fumigatus</i> Reveals Compartmentalization of Genotypes in Disseminated Disease after Invasive Pulmonary Aspergillosis. <i>Journal of Clinical Microbiology</i> , 2017 , 55, 331-333	9.7	3
100	Fungemia due to rare opportunistic yeasts: data from a population-based surveillance in Spain. <i>Medical Mycology</i> , 2017 , 55, 125-136	3.9	44
99	Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia. <i>Clinical Microbiology and Infection</i> , 2017 , 23, 49.e1-49.e8	9.5	30
98	In Vitro Exposure to Increasing Micafungin Concentrations Easily Promotes Echinocandin Resistance in <i>Candida glabrata</i> Isolates. <i>Antimicrobial Agents and Chemotherapy</i> , 2017 , 61,	5.9	23
97	Fluconazole-containing agar Sabouraud dextrose plates are not useful when screening for susceptibility in <i>Candida albicans</i> . <i>Revista Espanola De Quimioterapia</i> , 2017 , 30, 127-130	1.6	
96	Propensity Score Analysis of the Role of Initial Antifungal Therapy in the Outcome of <i>Candida glabrata</i> Bloodstream Infections. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3291-300	5.9	23
95	EUCAST technical note on isavuconazole breakpoints for <i>Aspergillus</i> , itraconazole breakpoints for <i>Candida</i> and updates for the antifungal susceptibility testing method documents. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 571.e1-4	9.5	78
94	Therapeutic drug monitoring of voriconazole helps to decrease the percentage of patients with off-target trough serum levels. <i>Medical Mycology</i> , 2016 , 54, 353-60	3.9	21
93	Risk factors for late recurrent candidaemia. A retrospective matched case-control study. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 277.e11-20	9.5	21
92	Susceptibility of <i>Candida albicans</i> biofilms to caspofungin and anidulafungin is not affected by metabolic activity or biomass production. <i>Medical Mycology</i> , 2016 , 54, 155-61	3.9	10

91	Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species. <i>Antimicrobial Agents and Chemotherapy</i> , 2016 , 60, 3579-86	5.9	14
90	Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score-derived analysis of a population-based, multicentre prospective cohort. <i>Clinical Microbiology and Infection</i> , 2016 , 22, 733.e1-8	9.5	26
89	Comparison of the antifungal activity of micafungin and amphotericin B against <i>Candida tropicalis</i> biofilms. <i>Journal of Antimicrobial Chemotherapy</i> , 2016 , 71, 2498-501	5.1	14
88	Scope and frequency of fluconazole trailing assessed using EUCAST in invasive <i>Candida</i> spp. isolates. <i>Medical Mycology</i> , 2016 , 54, 733-9	3.9	18
87	<i>Candida tropicalis</i> bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance. <i>Journal of Infection</i> , 2015 , 71, 385-94	18.9	28
86	<i>Candida</i> biomarkers in patients with candidaemia and bacteraemia. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2354-61	5.1	43
85	Epidemiology and outcome of candidaemia in patients with oncological and haematological malignancies: results from a population-based surveillance in Spain. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 491.e1-10	9.5	40
84	Clusters of patients with candidaemia due to genotypes of <i>Candida albicans</i> and <i>Candida parapsilosis</i> : differences in frequency between hospitals. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 677-83	9.5	11
83	A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 684.e1-9	9.5	15
82	The State-of-the-Art Mycology Laboratory: Visions of the Future. <i>Current Fungal Infection Reports</i> , 2015 , 9, 37-51	1.4	5
81	Multicenter study of isavuconazole MIC distributions and epidemiological cutoff values for the <i>Cryptococcus neoformans</i> - <i>Cryptococcus gattii</i> species complex using the CLSI M27-A3 broth microdilution method. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 666-8	5.9	49
80	Combination of <i>Candida</i> biomarkers in patients receiving empirical antifungal therapy in a Spanish tertiary hospital: a potential role in reducing the duration of treatment. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 3107-15	5.1	46
79	Multicenter study of epidemiological cutoff values and detection of resistance in <i>Candida</i> spp. to anidulafungin, caspofungin, and micafungin using the Sensititre YeastOne colorimetric method. <i>Antimicrobial Agents and Chemotherapy</i> , 2015 , 59, 6725-32	5.9	47
78	Next-generation sequencing offers new insights into the resistance of <i>Candida</i> spp. to echinocandins and azoles. <i>Journal of Antimicrobial Chemotherapy</i> , 2015 , 70, 2556-65	5.1	34
77	Training should be the first step toward an antifungal stewardship program. <i>Enfermedades Infecciosas Y Microbiología Clínica</i> , 2015 , 33, 221-7	0.9	15
76	Sputum and bronchial secretion samples are equally useful as bronchoalveolar lavage samples for the diagnosis of invasive pulmonary aspergillosis in selected patients. <i>Medical Mycology</i> , 2015 , 53, 235-40	3.9	13
75	Antifungal stewardship in a tertiary-care institution: a bedside intervention. <i>Clinical Microbiology and Infection</i> , 2015 , 21, 492.e1-9	9.5	55
74	Microsatellite (STRAf) genotyping cannot differentiate between invasive and colonizing <i>Aspergillus fumigatus</i> isolates. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 667-70	9.7	6

73	Aspergillus citrinoterreus, a new species of section Terrei isolated from samples of patients with nonhematological predisposing conditions. <i>Journal of Clinical Microbiology</i> , 2015 , 53, 611-7	9.7	28
72	ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 27-46	9.5	291
71	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 47-75	9.5	207
70	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 5-26	9.5	413
69	ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 3, 76-98	9.5	324
68	Production of biofilm by Candida and non-Candida spp. isolates causing fungemia: comparison of biomass production and metabolic activity and development of cut-off points. <i>International Journal of Medical Microbiology</i> , 2014 , 304, 1192-8	3.7	85
67	Is it feasible to diagnose catheter-related candidemia without catheter withdrawal?. <i>Medical Mycology</i> , 2014 , 52, 491-7	3.9	4
66	Initial use of echinocandins does not negatively influence outcome in Candida parapsilosis bloodstream infection: a propensity score analysis. <i>Clinical Infectious Diseases</i> , 2014 , 58, 1413-21	11.6	80
65	Is biofilm production a predictor of catheter-related candidemia?. <i>Medical Mycology</i> , 2014 , 52, 407-10	3.9	12
64	Micafungin is more active against Candida albicans biofilms with high metabolic activity. <i>Journal of Antimicrobial Chemotherapy</i> , 2014 , 69, 2984-7	5.1	13
63	Current challenges in the microbiological diagnosis of invasive aspergillosis. <i>Mycopathologia</i> , 2014 , 178, 403-16	2.9	15
62	Potential role of Candida albicans germ tube antibody in the diagnosis of deep-seated candidemia. <i>Medical Mycology</i> , 2014 , 52, 270-5	3.9	29
61	Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 5581-4	5.9	14
60	Is catheter-related candidemia a polyclonal infection?. <i>Medical Mycology</i> , 2014 , 52, 411-6	3.9	4
59	Invasive aspergillosis among heart transplant recipients: a 24-year perspective. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 278-88	5.8	41
58	Antifungal resistance to fluconazole and echinocandins is not emerging in yeast isolates causing fungemia in a Spanish tertiary care center. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 4565-72	5.9	37
57	Global trends in the distribution of Candida species causing candidemia. <i>Clinical Microbiology and Infection</i> , 2014 , 20 Suppl 6, 5-10	9.5	330
56	Invasive pulmonary aspergillosis in heart transplant recipients: two radiologic patterns with a different prognosis. <i>Journal of Heart and Lung Transplantation</i> , 2014 , 33, 1034-40	5.8	31

55	The Role of Antifungals against Candida Biofilm in Catheter-Related Candidemia. <i>Antibiotics</i> , 2014 , 4, 1-17	4.9	28
54	Molecular identification and antifungal susceptibility of yeast isolates causing fungemia collected in a population-based study in Spain in 2010 and 2011. <i>Antimicrobial Agents and Chemotherapy</i> , 2014 , 58, 1529-37	5.9	89
53	Endemic genotypes of Candida albicans causing fungemia are frequent in the hospital. <i>Journal of Clinical Microbiology</i> , 2013 , 51, 2118-23	9.7	19
52	Mixed bloodstream infections involving bacteria and Candida spp. <i>Journal of Antimicrobial Chemotherapy</i> , 2013 , 68, 1881-8	5.1	46
51	Is azole resistance in Aspergillus fumigatus a problem in Spain?. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 2815-20	5.9	63
50	Growth of Aspergillus in blood cultures: proof of invasive aspergillosis in patients with chronic obstructive pulmonary disease?. <i>Mycoses</i> , 2013 , 56, 488-90	5.2	6
49	Does identification to species level provide sufficient evidence to confirm catheter-related fungemia caused by Candida albicans?. <i>Medical Mycology</i> , 2013 , 51, 769-73	3.9	6
48	Comparison between the EUCAST procedure and the Etest for determination of the susceptibility of Candida species isolates to micafungin. <i>Antimicrobial Agents and Chemotherapy</i> , 2013 , 57, 5767-70	5.9	12
47	Evaluation of MycAssayAspergillus for diagnosis of invasive pulmonary aspergillosis in patients without hematological cancer. <i>PLoS ONE</i> , 2013 , 8, e61545	3.7	44
46	Rapid detection and identification of Aspergillus from lower respiratory tract specimens by use of a combined probe-high-resolution melting analysis. <i>Journal of Clinical Microbiology</i> , 2012 , 50, 3238-43	9.7	14
45	Characterization of clinical strains of Aspergillus terreus complex: molecular identification and antifungal susceptibility to azoles and amphotericin B. <i>Clinical Microbiology and Infection</i> , 2012 , 18, E24-8	9.5	19
44	Epidemiology, species distribution and in vitro antifungal susceptibility of fungaemia in a Spanish multicentre prospective survey. <i>Journal of Antimicrobial Chemotherapy</i> , 2012 , 67, 1181-7	5.1	107
43	Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit. <i>Clinical Infectious Diseases</i> , 2012 , 54, e24-31	11.6	56
42	In vitro acquisition of secondary azole resistance in Aspergillus fumigatus isolates after prolonged exposure to itraconazole: presence of heteroresistant populations. <i>Antimicrobial Agents and Chemotherapy</i> , 2012 , 56, 174-8	5.9	34
41	Candida tropicalis fungaemia: incidence, risk factors and mortality in a general hospital. <i>Clinical Microbiology and Infection</i> , 2011 , 17, 1538-45	9.5	53
40	Epidemiology and antifungal susceptibility of bloodstream fungal isolates in pediatric patients: a Spanish multicenter prospective survey. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 4158-63	9.7	47
39	Molecular epidemiology of Aspergillus fumigatus: an in-depth genotypic analysis of isolates involved in an outbreak of invasive aspergillosis. <i>Journal of Clinical Microbiology</i> , 2011 , 49, 3498-503	9.7	41
38	Aspergillus fumigatus strains with mutations in the cyp51A gene do not always show phenotypic resistance to itraconazole, voriconazole, or posaconazole. <i>Antimicrobial Agents and Chemotherapy</i> , 2011 , 55, 2460-2	5.9	41

37	Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. <i>Clinical Microbiology and Infection</i> , 2010 , 16, 870-7	9.5	236
36	Antifungal susceptibility, serotyping, and genotyping of clinical <i>Cryptococcus neoformans</i> isolates collected during 18 years in a single institution in Madrid, Spain. <i>Medical Mycology</i> , 2010 , 48, 942-8	3.9	37
35	Rapid antifungal susceptibility determination for yeast isolates by use of Etest performed directly on blood samples from patients with fungemia. <i>Journal of Clinical Microbiology</i> , 2010 , 48, 2205-12	9.7	32
34	In vitro antifungal activities of isavuconazole and comparators against rare yeast pathogens. <i>Antimicrobial Agents and Chemotherapy</i> , 2010 , 54, 4012-5	5.9	28
33	New antifungal agents for the treatment of candidaemia. <i>International Journal of Antimicrobial Agents</i> , 2010 , 36 Suppl 2, S63-9	14.3	7
32	Infectious and non-infectious neurologic complications in heart transplant recipients. <i>Medicine (United States)</i> , 2010 , 89, 166-175	1.8	37
31	Post-surgical invasive aspergillosis: an uncommon and under-appreciated entity. <i>Journal of Infection</i> , 2010 , 60, 162-7	18.9	37
30	Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum antifungal agents?. <i>Medical Mycology</i> , 2009 , 47, 515-20	3.9	6
29	In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. <i>Journal of Chemotherapy</i> , 2009 , 21, 272-81	2.3	52
28	Is <i>Candida</i> colonization of central vascular catheters in non-candidemic, non-neutropenic patients an indication for antifungals?. <i>Intensive Care Medicine</i> , 2009 , 35, 707-12	14.5	29
27	Prostatic aspergillosis in a heart transplant recipient: case report and review. <i>Journal of Heart and Lung Transplantation</i> , 2009 , 28, 638-46	5.8	3
26	Treatment of invasive fungal infections in immunocompromised and transplant patients: AmBiLoad trial and other new data. <i>International Journal of Antimicrobial Agents</i> , 2008 , 32 Suppl 2, S125-31	14.3	7
25	Relapsing <i>Rhodococcus equi</i> infection in a heart transplant recipient successfully treated with long-term linezolid. <i>Diagnostic Microbiology and Infectious Disease</i> , 2008 , 60, 197-9	2.9	16
24	Clinical isolates of <i>Aspergillus</i> species remain fully susceptible to voriconazole in the post-voriconazole era. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 3444-6	5.9	23
23	Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. <i>Future Microbiology</i> , 2008 , 3, 603-15	2.9	26
22	Value of a single galactomannan determination (Platelia) for the diagnosis of invasive aspergillosis in non-hematological patients with clinical isolation of <i>Aspergillus</i> spp. <i>Medical Mycology</i> , 2008 , 46, 575-9	3.9	27
21	Workload and clinical significance of the isolation of zygomycetes in a tertiary general hospital. <i>Medical Mycology</i> , 2008 , 46, 225-30	3.9	22
20	In vitro antifungal activities of isavuconazole (BAL4815), voriconazole, and fluconazole against 1,007 isolates of zygomycete, <i>Candida</i> , <i>Aspergillus</i> , <i>Fusarium</i> , and <i>Scedosporium</i> species. <i>Antimicrobial Agents and Chemotherapy</i> , 2008 , 52, 1396-400	5.9	177

19	Treatment options in emerging mold infections. <i>Current Infectious Disease Reports</i> , 2008 , 10, 473-9	3.9	7
18	Treatment options in emerging mold infections. <i>Current Fungal Infection Reports</i> , 2008 , 2, 74-80	1.4	3
17	Impact of zygomycosis on microbiology workload: a survey study in Spain. <i>Journal of Clinical Microbiology</i> , 2007 , 45, 2051-3	9.7	67
16	In vitro activities of amphotericin B, caspofungin, itraconazole, posaconazole, and voriconazole against 45 clinical isolates of zygomycetes: comparison of CLSI M38-A, Sensititre YeastOne, and the Etest. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 1126-9	5.9	50
15	Synergistic effect of posaconazole and caspofungin against clinical zygomycetes. <i>Antimicrobial Agents and Chemotherapy</i> , 2007 , 51, 3457-8	5.9	47
14	Mixed fungemia: incidence, risk factors, and mortality in a general hospital. <i>Clinical Infectious Diseases</i> , 2007 , 44, e109-14	11.6	41
13	Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of <i>Aspergillus fumigatus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2007 , 57, 273-6	2.9	21
12	Outdoor environmental levels of <i>Aspergillus</i> spp. conidia over a wide geographical area. <i>Medical Mycology</i> , 2006 , 44, 349-56	3.9	50
11	Fluconazole resistance mechanisms in <i>Candida krusei</i> : the contribution of efflux-pumps. <i>Medical Mycology</i> , 2006 , 44, 575-8	3.9	37
10	Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of <i>Aspergillus fumigatus</i> . <i>Diagnostic Microbiology and Infectious Disease</i> , 2006 , 56, 53-5	2.9	23
9	Update on invasive aspergillosis: clinical and diagnostic aspects. <i>Clinical Microbiology and Infection</i> , 2006 , 12, 24-39	9.5	39
8	Mucormycosis: an emerging disease?. <i>Clinical Microbiology and Infection</i> , 2006 , 12, 7-23	9.5	81
7	Evaluation of Czapeck agar and Sabouraud dextrose agar for the culture of airborne <i>Aspergillus</i> conidia. <i>Diagnostic Microbiology and Infectious Disease</i> , 2005 , 53, 333-4	2.9	7
6	Antifungal susceptibility of 596 <i>Aspergillus fumigatus</i> strains isolated from outdoor air, hospital air, and clinical samples: analysis by site of isolation. <i>Antimicrobial Agents and Chemotherapy</i> , 2005 , 49, 3495-7 ⁹	5.9	32
5	Workload due to <i>Aspergillus fumigatus</i> and significance of the organism in the microbiology laboratory of a general hospital. <i>Journal of Clinical Microbiology</i> , 2005 , 43, 2075-9	9.7	61
4	Effect of hypoxic conditions on in vitro susceptibility testing of amphotericin B, itraconazole and micafungin against <i>Aspergillus</i> and <i>Candida</i> . <i>Journal of Antimicrobial Chemotherapy</i> , 2004 , 53, 743-9	5.1	35
3	Evolution of the antimicrobial resistance of <i>Staphylococcus</i> spp. in Spain: five nationwide prevalence studies, 1986 to 2002. <i>Antimicrobial Agents and Chemotherapy</i> , 2004 , 48, 4240-5	5.9	57
2	Nosocomial invasive aspergillosis in a heart transplant patient acquired during a break in the HEPA air filtration system. <i>Transplant Infectious Disease</i> , 2004 , 6, 50-4	2.7	37

1 Extra-abdominal infections due to Gemella species. *International Journal of Infectious Diseases*,
2002, 6, 78-82

10.5 26